Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET ENCORE-CD
jRCT2071260024Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing JNJ-78934804 with Guselkumab (2 arms). Started Jun 2026; status: recruiting.
02
Drugs
guselkumab + golimumabguselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2071260024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260024.